EFFECTS OF GLYCYRRHIZIN PRE-TREATMENT ON TRANSIENT ISCHEMIC BRAIN INJURY IN MICE
DOI:
https://doi.org/10.21010/ajtcam.v14i5.15Keywords:
Glycyrrhizin, licorice, stroke, apoptosisAbstract
Background: Ischemia-induced brain damage is the leading cause of adult disability and the fifth leading cause of death, and thus, the development of anti-apoptotic neuro-protective therapeutic agents is viewed as an attractive developmental strategy. Glycyrrhizin is the main sweet component in licorice and has a number of pharmacological activities, which include neuro-protective, anti-fungal, and anti-cariogenic activities. This study was undertaken to investigate the effects of glycyrrhizin on ischemia-induced brain damage. Materials and Methods: In infarct volumes and the levels of several apoptosis-related proteins, caspase-3, - 8, 9, Bcl-xL, Bcl-2,and their activities in the brains of middle cerebral artery occlusion (MCAO) treated mice were measured using western blotting methods. Results: Single pre-treatment with glycyrrhizin (10-100 mg/kg)at 2 hours before MCAO significantly reduced infarct volumes at 24h after MCAO. In addition, glycyrrhizin effectively inhibited the activations of caspase-3 and -9 and the down-regulation of Bcl-xLprotein caused by MCAO. Conclusion: The neuro-protective effect of glycyrrhizin was found to be due to its regulation of apoptosisrelated proteins signals.The authors suggest glycyrrhizin be considered a potential candidate for the treatment of ischemia induced brain damage.Downloads
Published
How to Cite
Issue
Section
License
Copyright: Creative Commons Attribution CC.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.